Enfamil A+® has decades of smart, effective research behind it
Because the maker of Enfamil A+ is backed by more than 100 years of state-of-the-art scientific research.
For over a century, Mead Johnson, the maker of Enfamil A+, has combined expert research and an unwavering commitment to quality, bringing you formulas you can trust. Along with trust, this research has resulted in many meaningful innovations.
Hundreds of studies support your decision to feed Enfamil A+ to your precious baby.
Over the past four decades, Mead Johnson has conducted nearly 500 studies demonstrating our commitment to science-based innovation in paediatric nutrition. What does this help us do? It allows us to translate the latest findings into innovations that nourish infants and children better.
90 published studies. 60 clinical trials — and more.
When studies are important, others want to know about them. That’s why, since 2005, studies supported by Mead Johnson have resulted in nearly 90 published manuscripts. Clinical trials are important to not only our company, but also to our consumers. We supported more than 60 clinical trials in four important areas in 2013 alone: brain development, prematurity, immunology and allergy management.
Nutramigen A+® makes history as the #1 treatment for milk protein allergy.
For over 70 years, this effective formula has been helping babies with cow’s milk protein allergy feel better. With the publication of the 70th scientific study proving its effectiveness, the brand reached a milestone in 2011 — marking 70 years and 70 studies. Since that time, several more studies on Nutramigen A+ have been published — making Nutramigen A+ the most published and scientifically supported formula of its kind.
Enfamil A+ formulas have DHA for growing brains.
A baby’s brain more than doubles in size in the first year of life. A baby’s brain contains Omega-3 fat and most of that fat is DHA, an important building block of the brain. That’s why DHA is important for your child early in life. In fact, 9 out of 10 doctors agree that DHA-enriched nutrition is a practical way to support normal brain development. Formulas with DHA have been studied for over 20 years. Enfamil A+ formulas have DHA. These formulas are a good way to support normal brain development during the first year of life.
DHA contributes to the visual development of infants up to 12 months of age.
In 2009, Mead Johnson was the first and only company in the industry to receive a scientific endorsement from the European Food Safety Authority (EFSA) for this infant formula health claim. It went on to be approved by the European Commission and member States for publication. Well over 100 safety-related studies have been conducted on the sources of DHA and ARA used in our formulas, creating a unique and impressive database.
There’s nothing like a good start in life.
Mead Johnson believes that the nutrition received early in life makes a lifelong difference in health. That’s why our sole purpose is to advance and apply the science that helps shape the future of paediatric nutrition.